21 November 2022: Clinical Research
Long-Term Effect of Pancreaticoduodenectomy Combined with Revascularization for Resectable Pancreatic Carcinoma in Elderly Patients
Jiali Yang 1ABCDEF* , Zhengrong Xu 2ABCD* , Junfeng Zhang 1CD , Yao Zheng 1CD , Jianyou Gu 1AC , Qiang Zhou 1CD , Xianxing Wang 1CD , Shixiang Guo 1DF , Hongyu Zhang 3AD , Shengkai Chen 1ADG* , Huaizhi Wang 1ADG*DOI: 10.12659/MSM.938443
Med Sci Monit 2022; 28:e938443
Table 1 Comparison the demographic and clinical characteristics of the PDAC patients who underwent PDR according to age.
| Variables | Total (n=185) | Age <60 y (n=103) | 60 y ≤ Age <70 y (n=55) | Age ≥70 y (n=27) | P value |
|---|---|---|---|---|---|
| Male* | 121 (65.4) | 70 (68.0) | 33 (60.0) | 18 (66.7) | 0.599 |
| Tobacco* | 79 (42.7) | 44 (42.7) | 22 (40.0) | 13 (48.1) | 0.782 |
| Alcohol* | 63 (34.1) | 33 (32.0) | 19 (34.5) | 11 (40.7) | 0.694 |
| NRS 2002 ≥3* | 64 (34.6) | 26 (25.2) | 12 (21.8) | 26 (96.3) | 0.000 |
| ASA classification* | 0.000 | ||||
| I | 115 (62.2) | 77 (74.8) | 29 (52.7) | 9 (33.3) | |
| II | 70 (37.8) | 26 (25.2) | 26 (47.3) | 18 (66.7) | |
| Comorbidity* | 52 (28.1) | 18 (17.5) | 17 (30.9) | 17 (63.0) | 0.000 |
| Hypertension | 28 (15.1) | 10 (9.7) | 8 (14.5) | 10 (37.0) | 0.004 |
| Coronary artery disease | 5 (2.7) | 2 (1.9) | 0 (0) | 3 (11.1) | 0.026 |
| Diabetes mellitus | 26 (14.1) | 11 (10.7) | 10 (18.2) | 5 (18.5) | 0.306 |
| COPD | 8 (4.3) | 2 (1.9) | 2 (3.6) | 4 (14.8) | 0.023 |
| History of abdominal surgery* | 8 (4.3) | 3 (2.9) | 5 (9.1) | 0 (0) | 0.139 |
| Preoperative jaundice* | 123 (55.5) | 72 (70.0) | 35 (63.6) | 16 (59.3) | 0.503 |
| Preoperative biliary drainage* | 19 (10.3) | 11 (10.7) | 5 (9.1) | 3 (11.1) | 1.000 |
| Total bilirubin (μM/L)** | 138.4 (6.1–566.0) | 141.9 (6.1–476.5) | 135.0 (7.2–451.2) | 135.2 (7.8–566.0) | 0.682 |
| Haemoglobin (g/L)** | 124.0 (74.0–161.0) | 125.0 (81.0–161.0) | 121.0 (74.0–151.0) | 125.0 (81.0–161.0) | 0.259 |
| Albumin (g/L)** | 40.5 (26.9–55.1) | 41.0 (32.3–49.1) | 38.9 (28.0–55.1) | 40.4 (26.9–55.0) | 0.068 |
| White cell (10/L)** | 5.6 (1.4–13.8) | 5.7 (1.4–13.8) | 5.4 (3.0–10.2) | 5.4 (3.4–10.9) | 0.431 |
| Creatinine (μM/L)** | 61.0 (3.5–135.0) | 62.2 (3.5–135.0) | 59.0 (4.1–90.0) | 63 (36.3–106.0) | 0.326 |
| Prothrombin time (sec)** | 11.2 (3.5–59.0) | 11.3 (3.5–16.6) | 11.3 (9.5–59.0) | 11.4 (10.0–18.0) | 0.519 |
| CA19-9 (U/ml)** | 150.6 (1.7–1200.0) | 150.6 (1.7–900.0) | 123.0 (2.0–1000.0) | 170.2 (2.0–1200.0) | 0.540 |
| NRS 2002 – Nutritional risk screening 2002; ASA classification – American Society of Anaesthesiology classification; COPD – Chronic Obstructive Pulmonary Disease. * Results are presented as number (percentages); ** results are presented as median (range). | |||||